THURSDAY, Feb. 24, 2022 (HealthDay News) — An increase in telemedicine during the pandemic and easier access to prescription drugs to end a pregnancy may help explain why more than half of U.S. abortions are now done with a combination of medicines instead of surgery, researchers report.
The percentage of abortions done with U.S. Food and Drug Administration-approved mifepristone pills rose from about 44% in 2019 to 54% in 2020, according to preliminary numbers from the Guttmacher Institute, a research group that supports abortion rights.
Two factors may have contributed to the increase in the use of prescription pills for abortions, Guttmacher researcher Rachel Jones suggested.
During the pandemic, there was a rise in the use of telemedicine and the FDA started to allow abortion pills to be mailed to patients instead of requiring in-person visits to get them, a change that became permanent last December.
That means that millions of women can now get a prescription through an online consultation and receive the pills through the mail.
The FDA approved mifepristone (the main drug used in “medical abortions“) in 2000, and use of the abortion pills has been rising since then.
The recent increase “is not surprising, especially during COVID,” Dr. Marji Gold, a family medicine physician and abortion provider in New York City, told the Associated Press.
Patients seeking abortions at her clinic have long chosen the pills over the surgical procedure, she noted.
Abortion opponents have stepped up efforts to get state legislatures to place additional restrictions on medical abortions. So far this year, 16 state legislatures have proposed bans or restrictions on medication abortion, according to the Guttmacher Institute, the AP reported.
It said that mailing abortion pills is banned in three states — Arizona, Arkansas and Texas — and that 32 states require these medications to be prescribed by physicians even though other medicines can be prescribed by physician assistants and other health care providers.
More information
Visit the U.S. Food and Drug Administration for more on mifepristone.
SOURCE: Guttmacher Institute, news release, Feb. 24, 2022; Associated Press
Copyright © 2024 HealthDay. All rights reserved.